Congratulations to Dr. Michael Deininger for the award of a five year NIH grant from the National Cancer Institute. His new grant is entitled “Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL” and expands his successful research efforts in targeting the mutant BCR-ABL1 kinase in patients with chronic myelogenous leukemia.